Lurbinectedin domestic launch time

Lurbinectedin (Lurbinectedin) is a drug used to treat cancer. Specific indications include recurrent small cell lung cancer (SCLC) and recurrent synovial sarcoma (Myxoid/round cell liposarcoma). Rubicatin is approved to treat SCLC, a rare but aggressive subtype of lung cancer. Additionally, it is used to treat recurrent synovial sarcoma, a rare soft tissue tumor.

Rubicardin has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubicatin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.

Clinical trial data of Rubicatin shows that it can significantly extend progression-free survival (Progression-Free Survival, PFS) in some patients with relapsed SCLC and synovial sarcoma, thereby reducing the risk of disease progression. The use of rubicatin may be associated with some side effects, including fatigue, nausea, vomiting, and loss of appetite. However, these side effects can usually be mitigated with a doctor's supervision and management.

In summary, rubicatin is a promising treatment that offers new treatment options for patients with certain rare cancer types. It has a unique mechanism of action and is expected to play an important role in controlling the growth and spread of cancer. However, treatment decisions should be made jointly by physician and patient, taking into account the patient's specific condition and treatment goals. Further research and clinical trials will continue to evaluate the efficacy and safety of rubicatin to provide patients with better treatment options.